Lexaria Bioscience Corp.
NASDAQ Capital MarketTotal Valuation
Lexaria Bioscience Corp. carries a market capitalization of 29,730.00, placing it among publicly traded companies globally. Its enterprise value stands at -3.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 29,730.00 |
| Enterprise Value | -3.92M |
Share Statistics
Lexaria Bioscience Corp. currently has 1.65M shares outstanding.
| Shares Outstanding | 1.65M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 2.09 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Lexaria Bioscience Corp. maintains a current ratio of 10.60, meaning it holds 10.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.60 |
| Quick Ratio | 9.56 |
| Debt / Equity | 2.00 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -150.28 |
| Return on Assets (ROA) | -134.21 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 4,403.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Lexaria Bioscience Corp.'s stock has declined approximately -99.5% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.5% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.16 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -7.63M, while operating income came in at -7.71M.
| Revenue | 194,000.00 |
| Gross Profit | 194,000.00 |
| Operating Income | -7.71M |
| Pretax Income | -7.74M |
| Net Income | -7.73M |
| EBITDA | -7.63M |
| EBIT | -7.71M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Lexaria Bioscience Corp. holds 3.62M in cash and equivalents against 86,714.00 in total debt, resulting in a net debt position of -3.48M. Total book value stands at 4.74M, with working capital of 3.68M providing operational flexibility.
| Cash & Cash Equivalents | 3.62M |
| Total Debt | 86,714.00 |
| Net Debt | -3.48M |
| Equity (Book Value) | 4.74M |
| Book Value Per Share | 2.87 |
| Working Capital | 3.68M |
Cash Flow
Lexaria Bioscience Corp. produced -7.43M in operating cash flow over the past twelve months.
| Operating Cash Flow | -7.43M |
| Capital Expenditures | -101,872.00 |
| Free Cash Flow | -7.53M |
| FCF Per Share | N/A |
Margins
Lexaria Bioscience Corp. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -3,973.16 and net profit margin of -3,985.58 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -3,973.16 |
| Pretax Margin | -3,987.65 |
| Profit Margin | -3,985.58 |
| EBITDA Margin | -3,933.69 |
Scores
Lexaria Bioscience Corp. posts an Altman Z-Score of -26.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -26.27 |